Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors

被引:51
作者
Ylisastigui, L
Coull, JJ
Rucker, VC
Melander, C
Bosch, RJ
Brodie, SJ
Corey, L
Sodora, DL
Dervan, PB
Margolis, DM
机构
[1] Univ Texas, SW Med Ctr, Dept Med, Div Infect Dis, Dallas, TX 75390 USA
[2] N Texas Vet Hlth Care Syst, Dallas, TX USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[4] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[5] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA
关键词
D O I
10.1086/423822
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The persistence of human immunodeficiency virus (HIV) type 1 within resting CD4(+) T cells poses a daunting therapeutic challenge. Histone deacetylase (HDAC)-1, a chromatin-remodeling enzyme that can mediate gene silencing, is recruited to the HIV-1 long terminal repeat by the host transcription factor LSF. Pyrrole-imidazole polyamides, small molecules that target specific DNA sequences, can access the nucleus of cells and specifically block transcription-factor binding. Methods. We used polyamides to directly test the role of chromatin remodeling in HIV quiescence in primary resting CD4(+) T cells obtained from HIV-infected patients. Results. After exposure to any of 4 different polyamides that specifically block HDAC-1 recruitment by LSF to the HIV promoter, replication-competent HIV was recovered from cultures of resting CD4(+) T cells in 6 of 8 HIV-infected patients whose viremia had been suppressed by therapy. In comparison, HIV was not recovered after exposure to control, mismatched polyamides but was recovered from 7 of 8 of these patients' samples after the activation of T cells. Conclusions. We identify histone deacetylation as a mechanism that can dampen viral expression in infected, activated CD4(+) T cells and establish a persistent, quiescent reservoir of HIV infection.
引用
收藏
页码:1429 / 1437
页数:9
相关论文
共 50 条
[31]   Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy [J].
Pierson, T ;
McArthur, T ;
Siliciano, RF .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :665-708
[32]   Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy [J].
Prins, JM ;
Jurriaans, S ;
van Praag, RME ;
Blaak, H ;
van Rij, R ;
Schellekens, PTA ;
ten Berge, IJM ;
Yong, SL ;
Fox, CH ;
Roos, MTL ;
de Wolf, F ;
Goudsmit, J ;
Schuitemaker, H ;
Lange, JMA .
AIDS, 1999, 13 (17) :2405-2410
[33]   Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-κB and inhibitors of deacetylases:: Potential perspectives for the development of therapeutic strategies [J].
Quivy, V ;
Adam, E ;
Collette, Y ;
Demonte, D ;
Chariot, A ;
Vanhulle, C ;
Berkhout, B ;
Castellano, W ;
de Launoit, Y ;
Burny, AN ;
Piette, J ;
Bours, V ;
Van Lint, C .
JOURNAL OF VIROLOGY, 2002, 76 (21) :11091-11103
[34]   The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy [J].
Ramratnam, B ;
Mittler, JE ;
Zhang, LQ ;
Boden, D ;
Hurley, A ;
Fang, F ;
Macken, CA ;
Perelson, AS ;
Markowitz, M ;
Ho, DD .
NATURE MEDICINE, 2000, 6 (01) :82-85
[35]   Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays [J].
Rodrigo, AG ;
Goracke, PC ;
Rowhanian, K ;
Mullins, JI .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (09) :737-742
[36]   Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF [J].
Romerio, F ;
Gabriel, MN ;
Margolis, DM .
JOURNAL OF VIROLOGY, 1997, 71 (12) :9375-9382
[37]   HIV-1 integration in the human genome favors active genes and local hotspots [J].
Schröder, ARW ;
Shinn, P ;
Chen, HM ;
Berry, C ;
Ecker, JR ;
Bushman, F .
CELL, 2002, 110 (04) :521-529
[38]   Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype [J].
Scripture-Adams, DD ;
Brooks, DG ;
Korin, YD ;
Zack, JA .
JOURNAL OF VIROLOGY, 2002, 76 (24) :13077-13082
[39]   Histone acetyltransferases regulate HIV-1 enhancer activity in vitro [J].
Sheridan, PL ;
Mayall, TP ;
Verdin, E ;
Jones, KA .
GENES & DEVELOPMENT, 1997, 11 (24) :3327-3340
[40]   Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells [J].
Siliciano, JD ;
Kajdas, J ;
Finzi, D ;
Quinn, TC ;
Chadwick, K ;
Margolick, JB ;
Kovacs, C ;
Gange, SJ ;
Siliciano, RF .
NATURE MEDICINE, 2003, 9 (06) :727-728